Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

Utility of Exercise-induced NT-pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00567437

Acronym

AS-BNP

Enrollment

110

Registered

2007-12-05

Start date

2007-12-31

Completion date

2008-12-31

Last updated

2012-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Stenosis

Keywords

aortic stenosis, prognosis, brain natriuretic peptide

Brief summary

One hundred patients with moderate to severe asymptomatic aortic stenosis (AS) will be asked to exercise on a treadmill. NT-pro-BNP levels will be drawn before and after exercise. Changes in NT-pro-BNP levels will be correlated to outcomes at one year. In the pilot phase an additional 10 control subjects without AS will be enrolled to document the control response of NT-pro-BNP elevations with exercise.

Interventions

OTHERNT-pro-BNP levels

pre- and post-exercise NT-pro-BNP levels

Study design

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. valvular AS (Doppler velocity ≥ 3.0 m/s) 2. no baseline symptoms referable to valvular heart disease 3. able to perform ETT

Exclusion criteria

1. more than mild aortic regurgitation, mitral regurgitation/ stenosis, or tricuspid regurgitation/stenosis 2. previous AVR 3. known coronary artery disease 4. creatinine clearance 50 mL/min 5. LVEF \< 50% 6. planned valve surgery prior to enrollment 7. significant pulmonary disease 8. unable to give informed consent 9. pregnancy

Design outcomes

Primary

Measure	Time frame
development of symptomatic aortic stenosis (new/progressive angina or dyspnea, pre-syncope/syncope, hospitalization for cardiac chest pain or heart failure, drop in LV ejection fraction, cardiovascular or sudden death, valve replacement surgery)	one year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026